Oncolytic adenovirus-mediated delivery of anti-CLDN18.2 IgG3 for the treatment of solid tumors
Abstract Background Claudin 18.2 (CLDN18.2) is a promising therapeutic target for gastric, pancreatic and ovarian cancers. The Food and Drug Administration-approved antibody, zolbetuximab (IgG1), induces tumor cell death via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis...